Product Description: Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models[1][2][3][4].
Applications: Neuroscience-Neuromodulation
Formula: C27H45N4O8P
References: [1]Leen H. KAWAS, et al. WO2017210489. 2021./[2]Reda SM, et al. Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease. Neurotherapeutics. 2024 Jul;21(4):e00350. /[3]Johnston JL, et al. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. 2023 Mar;20(2):431-451./[4]Reda S, et al. Fosgonimeton, a novel, small molecule positive modulator of the HGF/MET system is neuroprotective in primary neuron culture. Alzheimer's Dement. 2022 18: e065874.
CAS Number: 2093305-05-4
Molecular Weight: 584.64
Compound Purity: 98.24
Research Area: Neurological Disease
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: c-Met/HGFR
English
Deutsch
